Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mucin Concentration Used As Bronchitis Biomarker

By LabMedica International staff writers
Posted on 22 Sep 2017
Chronic bronchitis is characterized by recurring bouts of airway inflammation accompanied by a persistent cough and phlegm production. It is different from acute bronchitis, which typically develops after a cold or influenza and only lasts a few weeks.

Chronic obstructive pulmonary disease (COPD) is typified by chronic bronchitic and emphysematous components. The concentration of mucins, the proteins that make mucus thick, is abnormally high in chronic bronchitis and that high mucin concentrations are associated with disease severity in people with chronic bronchitis.

A large team of scientists working with those at University of North Carolina (Chapel Hill, NC, USA) characterized the COPD status of 917 participants from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) using questionnaires administered to participants, chest tomography, spirometry, and examination of induced sputum. Total mucin concentrations in sputum were measured with the use of size-exclusion chromatography and refractometry. In 148 of these participants, the respiratory secreted mucins MUC5AC and MUC5B were quantitated by means of mass spectrometry. Data from chronic-bronchitis questionnaires and data on total mucin concentrations in sputum were also analyzed in an independent 94-participant cohort.

The scientists found that the mean (± SE) total mucin concentrations were higher in current or former smokers with severe COPD than in controls who had never smoked (3,166 ± 402 versus 1,515 ± 152 μg/mL) and were higher in participants with two or more respiratory exacerbations per year than in those with zero exacerbations (4,194 ± 878 versus 2,458 ±113 μg/mL). The absolute concentrations of MUC5B and MUC5AC in current or former smokers with severe COPD were approximately three times as high and 10 times as high, respectively, as in controls who had never smoked. The study is significant not only because it suggests mucins can be used as a biomarker for diagnosing and predicting the risk for chronic bronchitis, but also because it offers new scientific tools to measure mucin concentrations.

Mehmet Kesimer, PhD, an associate professor of pathology and laboratory medicine and the lead author of the study, said, “We really wanted to see if we could use this measure to predict risk, in the same way that we use cholesterol measurements to predict cardiovascular disease. We plan to look for ways to translate our findings into a practical test that could find its way into your doctor's office, not just for chronic bronchitis but also for other muco-obstructive diseases of the lung, such as bronchiectasis and asthma.” The study was published on September 7, 2017, in The New England Journal of Medicine.

Related Links:
University of North Carolina


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.